BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19778431)

  • 21. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
    Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
    JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Postoperative fever: the potential relationship with prognosis in node negative breast cancer patients.
    Yan T; Yin W; Zhou L; Jiang Y; Shen Z; Shao Z; Lu J
    PLoS One; 2010 Dec; 5(12):e15903. PubMed ID: 21209958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast carcinoma subtypes show different patterns of metastatic behavior.
    Molnár IA; Molnár BÁ; Vízkeleti L; Fekete K; Tamás J; Deák P; Szundi C; Székely B; Moldvay J; Vári-Kakas S; Szász MA; Ács B; Kulka J; Tőkés AM
    Virchows Arch; 2017 Mar; 470(3):275-283. PubMed ID: 28101678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.
    Gonzalez-Angulo AM; Litton JK; Broglio KR; Meric-Bernstam F; Rakkhit R; Cardoso F; Peintinger F; Hanrahan EO; Sahin A; Guray M; Larsimont D; Feoli F; Stranzl H; Buchholz TA; Valero V; Theriault R; Piccart-Gebhart M; Ravdin PM; Berry DA; Hortobagyi GN
    J Clin Oncol; 2009 Dec; 27(34):5700-6. PubMed ID: 19884543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast-Conserving Therapy Versus Mastectomy in Young Breast Cancer Patients Concerning Molecular Subtypes: A SEER Population-Based Study.
    Yu P; Tang H; Zou Y; Liu P; Tian W; Zhang K; Xie X; Ye F
    Cancer Control; 2020; 27(1):1073274820976667. PubMed ID: 33356518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.
    Darlix A; Griguolo G; Thezenas S; Kantelhardt E; Thomssen C; Dieci MV; Miglietta F; Conte P; Braccini AL; Ferrero JM; Bailleux C; Jacot W; Guarneri V
    J Neurooncol; 2018 Jun; 138(2):369-382. PubMed ID: 29488184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990-2011.
    Malmgren J; Hurlbert M; Atwood M; Kaplan HG
    Breast Cancer Res Treat; 2019 Apr; 174(2):505-514. PubMed ID: 30560462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?
    Sheridan W; Scott T; Caroline S; Yvonne Z; Vanessa B; David V; Karen G; Stephen C
    Breast Cancer Res Treat; 2014 Oct; 147(3):617-29. PubMed ID: 25209005
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Low Tumor Endothelial Cell pY397-Focal Adhesion Kinase Expression With Survival in Patients With Neoadjuvant-Treated Locally Advanced Breast Cancer.
    Roy-Luzarraga M; Abdel-Fatah T; Reynolds LE; Clear A; Taylor JG; Gribben JG; Chan S; Jones L; Hodivala-Dilke K
    JAMA Netw Open; 2020 Oct; 3(10):e2019304. PubMed ID: 33107920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparison of biological behavior between triple-negative breast cancer and non-triple- negative breast cancer].
    Ma JG; Wang NJ; Yu WJ
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1729-32. PubMed ID: 22027778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Locoregional recurrence by molecular subtype after multicatheter interstitial accelerated partial breast irradiation: Results from the Pooled Registry Of Multicatheter Interstitial Sites research group.
    Anderson BM; Kamrava M; Wang PC; Chen P; Demanes DJ; Hayes JK; Kuske RR
    Brachytherapy; 2016; 15(6):788-795. PubMed ID: 27743957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of metastatic pattern in stage IV breast cancer at initial diagnosis.
    Leone BA; Vallejo CT; Romero AO; Machiavelli MR; Pérez JE; Leone J; Leone JP
    Breast Cancer Res Treat; 2017 Feb; 161(3):537-548. PubMed ID: 27975154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
    Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes.
    Buonomo OC; Caredda E; Portarena I; Vanni G; Orlandi A; Bagni C; Petrella G; Palombi L; Orsaria P
    PLoS One; 2017; 12(9):e0184680. PubMed ID: 28922402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis.
    Gu Y; Wu G; Zou X; Huang P; Yi L
    Med Sci Monit; 2020 Feb; 26():e920432. PubMed ID: 32043484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast-conserving therapy for triple-negative breast cancer.
    Gangi A; Chung A; Mirocha J; Liou DZ; Leong T; Giuliano AE
    JAMA Surg; 2014 Mar; 149(3):252-8. PubMed ID: 24382582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.
    Diessner J; Wischnewsky M; Stüber T; Stein R; Krockenberger M; Häusler S; Janni W; Kreienberg R; Blettner M; Schwentner L; Wöckel A; Bartmann C
    BMC Cancer; 2016 May; 16():307. PubMed ID: 27175930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
    Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
    J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
    Thangarajah F; Vogel C; Pahmeyer C; Eichler C; Holtschmidt J; Ratiu D; Mallmann P; Malter W
    Anticancer Res; 2018 Oct; 38(10):6023-6026. PubMed ID: 30275235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.